The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), according to The New York Times.

A U.S. humanitarian waiver will allow people in several countries to continue accessing life-saving HIV treatments, the UNAIDS said on Wednesday, after President Donald Trump's freeze on foreign aid threatened such supplies.

The President’s Emergency Plan for AIDS Relief (PEPFAR), a federal program that provides HIV medications, is one of the programs on pause during a 90-day review ordered by the Secretary of State.

A stop in all of PEPFAR’s work shuttered clinics this week. Then, a new exemption for “life-saving” treatment left organizations uncertain.

Nigeria has the highest number of people living with HIV in the West and Central African region. Over the past two decades, partners

Almost 1 in 10 patients receiving HIV care may have binge eating disorder (BED), a significantly higher rate than the 0.3% reported in the general population, according to a cross-sectional study. Individuals with possible BED were six times more likely than others to have clinical obesity and twice as likely to be overweight.

The objectives of the research presented in this report were to identify case studies of community-led HIV-related health and social inclusion service delivery organizations in eastern and southern Africa;

The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria, and tuberculosis in countries supported by USAID around the globe.

Marco Rubio, US Secretary of State, has authorised an “Emergency Humanitarian Waiver” that ensures continued access to HIV treatment.

The President’s Emergency Program for AIDS Relief is in danger of shuttering. The decision could kill hundreds of thousands of people and kickstart an epidemic.

A map of deadly infectious diseases known to attack the central nervous system (CNS) of people who are already suffering with HIV has unearthed diagnosis "blank spots" in Africa, according to research published today in The Lancet Global Health.